HEB Gets Some Relief, ITEK Awaits Data In Dec., NYMX Abuzz, FDA Snubs AMGN

The FDA has turned down Amgen Inc.'s (AMGN) Parsabiv, proposed for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.

from RTT - Biotech http://ift.tt/2bHN5AB
via IFTTT